• Clinical Insights: July 7, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  ByfavoTM (remimazolam) Injection – New Drug Approval – July 2, 2020 – Cosmo Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Byfavo™ (remimazolam injection)… Read more »

  • Clinical Insights: June 30, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Fintepla® (fenfluramine) Oral Solution – New Drug Approval – June 26, 2020 – The U.S. Food and Drug Administration approved Fintepla® (fenfluramine), a Schedule IV controlled substance, for… Read more »

  • Clinical Insights: June 23, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  GimotiTM (metoclopramide) Nasal Spray – New Drug Approval – June 19, 2020 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced… Read more »

  • Clinical Insights: June 16, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  ZepzelcaTM (lurbinectedin) Injection – New Drug Approval – June 15, 2020 – PharmaMar announced, along with Jazz Pharmaceuticals plc, that the U.S. Food and Drug Administration (FDA) has… Read more »

  • Clinical Insights: June 9, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval No new update. New Formulation Approval No new update. New Indication Approval RecarbrioTM (imipenem-cilastatin and relebactam) Injection – New Drug Indication Approval – June 4, 2020 –… Read more »

  • Clinical Insights: June 2, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval OriahnnTM (elagolix/estradiol/norethindrone acetate and elagolix) Capsules – New Drug Approval – May 29, 2020 – The U.S. Food and Drug Administration granted approval to OriahnnTM (an estrogen and… Read more »

  • Clinical Insights: May 27, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval PhexxiTM (lactic acid, citric acid and potassium bitartrate) Vaginal Gel – New Drug Approval – May 22, 2020 – Evofem Biosciences, Inc. announced that the U.S. Food… Read more »

  • Connect with RxStrategies at the 2020 Virtual Spring Hospital Pharmacy Conference

    RxStrategies’ Rhodie Smith will attend the 2020 Virtual Spring Hospital Pharmacy Conference. Providing educational sessions and meeting opportunities, the conference brings industry providers and suppliers together in a new virtual event format to learn, connect, and support each other.   Utilizing its virtual format, the conference will also include a Virtual Reverse Expo, which facilitates… Read more »

  • Clinical Insights: May 19, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval QinlockTM (ripretinib) Tablets – New Drug Approval – May 15, 2020 – The U.S. Food and Drug Administration approved QinlockTM (ripretinib) tablets as the first new drug specifically… Read more »

  • Clinical Insights: May 12, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval RetevmoTM (selpercatinib) Capsules – New Drug Approval – May 8, 2020 – The U.S. Food and Drug Administration approved RetevmoTM (selpercatinib) capsules to treat three types of tumors… Read more »